NBDC Research ID: hum0194.v1
SUMMARY
Aims: To study the molecular mechanisms of drug resistance in lung cancer patients by using of their tumor cells
Methods: Target Capture Sequencing
Participants/Materials: tumor tissues from ROS1-rearranged non-small cell lung cancer patients
| Dataset ID | Type of Data | Criteria | Release Date |
|---|---|---|---|
| JGAS000189 | NGS (Target Capture) | Controlled-access (Type I) | 2020/05/11 |
*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more
MOLECULAR DATA
| Participants/Materials | Lung adenocarcinoma (ICD10: C34): 2 cases |
| Targets | Target Capture |
| Target Loci for Capture Methods |
ABL1, AKT1, AKT3, ALK, APC, ATM, AXL, BCL2L11, BRAF, BRCA1, BRCA2, CCND1, CDH1, CD274, CDKN2A, CFTR, CREBBP, CSF1R, CTNNA3, CTNNB1, CUL3, DCC, EGFR, EPHA2, EPHA7, ERBB2, ERBB3, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXA1, FOXP1, GNA11, GNAQ, GNAS, GRM3, HGF, HNF1A, HRAS, IDH1, IDH2, IGF1R, JAK2, JAK3, KDR, KEAP1, KIT, KLF4, KRAS, MAP2K1, MAP2K2, MC1R, MCL1, MED12, MERTK, MET, MITF, MLH1, MLL2, MLL3, MPL, MSH2, MSH6, MTOR, MYC, MYCN, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3C2B, PIK3CA, PIK3CG, PMS2, PTCH1, PTEN, PTPN11, RAC1, RAC2, RB1, RET, ROCK2, ROS1, SH2B3, SLIT2, SMAD4, SMARCA4, SMARCB1, SMO, SOX2, SPOP, SRC, STK11, TP53, TRAF7, TSC1, TSC2, VHL |
| Platform | Illumina [MiSeq] |
| Library Source | DNAs extracted from tumor tissues |
| Cell Lines | - |
| Library Construction (kit name) | Agilent HaloPlex HS Custom Kits |
| Fragmentation Methods | Enzymatic fragmentation (included in the above library construction kit) |
| Spot Type | Paired-end |
| Read Length (without Barcodes, Adaptors, Primers, and Linkers) | 150 bp |
| Japanese Genotype-phenotype Archive Dataset ID | JGAD000272 |
| Total Data Volume | 128 MB (bam, vcf [ref: hg38]) |
| Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Ryohei Katayama
Affiliation: Japanese Foundation for Cancer Research
Project / Group Name: Div of Exp Chemother, Cancer Chemotherapy Center
URL： https://www.jfcr.or.jp/english/chemotherapy/department/fundamental/index.html
Funds / Grants (Research Project Number):
| Name | Title | Project Number |
|---|---|---|
| KAKENHI Grant-in-Aid for Scientific Research (B) | Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancers | 16H04715 |
| KAKENHI Grant-in-Aid for Scientific Research (B) | Molecular mechanisms of drug tolerant persister cells emergence after molecular target therapy in lung cancer | 19H03524 |
| KAKENHI Grant-in-Aid for Scientific Research (A) | Molecular analysis of acquired resistance to targeted therapies and search for overcoming drugs | 15H02368 |
| KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area) | Integrated analysis and regulation of cellular diversity for disease treatment | 17H06327 |
| Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED) | Development of combined strategy for treatment of drug-insensitive cancers with advanced technologies in interdisciplinary research areas | JP19cm0106203 |
| Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) | Mechanisms of checkpoint inhibitor resistance through secretable immunosuppressive variants | JP19ck0106472 |
PUBLICATIONS
| Title | DOI | Dataset ID | |
|---|---|---|---|
| 1 | The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models | doi: 10.1038/s41467-019-11496-z | JGAD000272 |
| 2 |
USRES (Controlled-access Data)
| Principal Investigator | Affiliation | Country/Region | Research Title | Data in Use (Dataset ID) | Period of Data Use |
|---|---|---|---|---|---|
| Hirofumi Nakaoka | Department of Cancer Genome Research, Sasaki Institute | Japan | Genetic analysis of lung cancer | JGAD000272 | 2022/08/06-2023/03/31 |
